Co-Culture Kit hAstroPro-NeuroNet

add to cart
Catalog: hANN141.27 | $1217.00 US | $1515.00 International

hAstroPro™-NeuroNet™ Co-Culture Kit is an ideal in vitro system that provides a more complete and robust means to address neurotoxicity and developmental neurotoxicity. This system models the later stages of neurons combined with astrocytes and is tunable and customizable to your application layouts.

hAstroPro™ Human Astrocyte Cells are derived from human pluripotent stem cell line h9 (NIH registry number 0062) and are the first highly characterized hESC derived CNS support cell type commercially available. hAstroPro™ cells are derived using a chemically defined method that enables shortened differentiation and scaled uniform production.

Ideal for use in studies of glial development and for use in co-culture systems with ArunA's  NeuroNet™ Pure Human Neurons.

  • Genetically uniform supply of human astrocyte cells
  • Uniform adherent astrocyte morphology
  • Express a repertoire of astrocytic genes
  • Non-transformed
  • Serum free

 

 

 

 

 

Contact us: info@arunabiomedical.com

NeuroNet™ Pure Human Neurons are a highly pure population of hPSC derived neurons developed with versatility in mind. NeuroNet™ Human Neurons enable rapid response in a relevant in vitro culture model system and have been strategically designed for co-culture cellular model studies with hAstroPro Human Astrocytes.

NeuroNet™ Pure Human Neurons can be cultured in an adherent 96-well format with ArunA’s proprietary culture medium and neural supplement and can be maintained in culture for longitudinal studies during which time NeuroNet cells have demonstrated extensive neurite outgrowth and synapse formation.

NeuroNet™ Pure Human Neurons are derived from WA09 human embryonic stem cells by ArunA Biomedical using a proprietary process under defined feeder-free & serum-free conditions. These differentiated neurons are cryopreserved for ready, convenient use.

Catelog#hANN141.27 contains the following components:

PART NUMBER UNITS DESCRIPTION

hAP7027

hJL7014

7011.3

7011.4

1

2

1

2

hAstroPro Human Astrocytes

NeuroNet Pure Human Neurons

AB2 Basal Neural Medium 1x500mL

ANS Neural Medium Supplement 2 x 5mL

Cell Type:  Astrocytes
Part Number:  hAP7027
Species:  human
Source:  derived from h9 hESC (NIH registry number 0062)
Morphology:  glial
Quantity:  ~1x106cells per vial
Shipping method:  dry ice
Storage:  liquid nitrogen
Growth Properties:  adherent
Medium:  AB2™ Basal Neural Medium with ANS™ Neural Medium Supplement plus additional unsupplied reagents.
Purity as determinded by ICC: S100β, CD44, BDNF, GFAP, Vimentin.

 

Cell Type:  Neuron
Part Number:  hJL7014
Species:  human
Source:  derived from human embryonic cell line, H9 (WA09)
Morphology:  neuronal
Quantity:  ~7x105 cells per vial
Shipping method:  dry ice
Storage:  liquid nitrogen
Growth Properties:  adherent, non-proliferative
Medium AB2™ Basal Neural Medium with ANS™ Neural Medium Supplement plus LIF (10 mg/mL)
Phenotyping:  Cells are >95% β III tubulin positive and >98% MAP2 positive.

DNA fingerprint:  Results are consistent with the presence of a single cell line with no evidence of culture cross contamination. The loci match the DNA fingerprint pattern for the H9 (NIH designation, WA09) hESC line as published in http://stemcells.nih.gov/research/nihresearch/scunit/.

Pathogen testing:   This lot was derived from the H9 hESC line that has been tested for Hepatitis B, Hepatitis C, HIV-1, HIV-2, HTLV-I/II, HSV1, HSV2, EBV, and CMV.  The H9 cell line has been tested and shown to be negative (performed by GIVF Laboratories).  Cells are tested for sterility and mycoplasma contamination.

Media Components:

AB2 Basal Neural Medium

ANS Neural Medium Supplement

Please note additional reagents are recommended but not supplied.

Reference:

Inhibition of DNA methyltransferases and histone deacetylases induces astrocytic differentiation of neural progenitors.

Working bank DNA fingerprint:  Results are consistent with the presence of a single cell line with no evidence of culture cross contamination. The loci match the DNA fingerprint pattern for the H9 (NIH designation, ) hESC line as published in http://stemcells.nih.gov/research/nihresearch/scunit/.

Working bank pathogen testing:   This lot was derived from the H9 hESC line that has been tested for Hepatitis B, Hepatitis C, HIV-1, HIV-2, HTLV-I/II, HSV1, HSV2, EBV, and CMV.  The H9 cell line has been tested and shown to be negative (performed by GIVF Laboratories).  Cells are also tested for sterility and mycoplasma contamination.

Technical Information:

For additional information contact us at info@arunabiomedical.com or call 706-542-4941.

 

Product Use Agreement

BIOLOGICAL PRODUCT(S) purchased from ArunA Biomedical shall not be: (i) used for any purpose other than internal research and internal research services, (ii) sold or otherwise provided to any third party for any use or purpose, or (iii) provided to any agent or other third party to provide services and or other services. Acceptance of BIOLOGICAL PRODUCT(S) from ArunA Biomedical shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires ArunA Biomedical prior written authorization. BIOLOGICAL PRODUCT(S) may not be used for diagnostic or therapeutic purposes.

 

 

Reference:

Inhibition of DNA methyltransferases and histone deacetylases induces astrocytic differentiation of neural progenitors.

Working bank DNA fingerprint:  Results are consistent with the presence of a single cell line with no evidence of culture cross contamination. The loci match the DNA fingerprint pattern for the H9 (NIH designation, ) hESC line as published in http://stemcells.nih.gov/research/nihresearch/scunit/.

Working bank pathogen testing:   This lot was derived from the H9 hESC line that has been tested for Hepatitis B, Hepatitis C, HIV-1, HIV-2, HTLV-I/II, HSV1, HSV2, EBV, and CMV.  The H9 cell line has been tested and shown to be negative (performed by GIVF Laboratories).  Cells are also tested for sterility and mycoplasma contamination.

Technical Information:

For additional information contact us at info@arunabiomedical.com or call 706-542-4941.

 

Product Use Agreement

BIOLOGICAL PRODUCT(S) purchased from ArunA Biomedical shall not be: (i) used for any purpose other than internal research and internal research services, (ii) sold or otherwise provided to any third party for any use or purpose, or (iii) provided to any agent or other third party to provide services and or other services. Acceptance of BIOLOGICAL PRODUCT(S) from ArunA Biomedical shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires ArunA Biomedical prior written authorization. BIOLOGICAL PRODUCT(S) may not be used for diagnostic or therapeutic purposes.

 

1ArunA Biomedical, Inc. Athens, GA, USA, 2Regenerative Bioscience Center, 3Interdisciplinary Toxicology Program, University of Georgia, Athens, GA, USA

Introduction: There is a need for rapid and cost effective methods to identify chemicals hazardous to human brain development. Brain development follows a fairly long but defined timeline; comprised of developmental windows each dominated by specific cell types and processes, potentially presenting unique susceptibilities. To accurately assess risk it is thus critical to address developmental neurotoxicity (DNT) in the context of progressive windows of susceptibility (WOS) as well as different cell types, alone or in tissue representative combinations. Here we present anin vitro system; using human pluripotent stem cell (hPSC) derived neural progenitors to model an early proliferative phase, neuronal cells at partial and advanced stages of differentiation to model later stages, and neurons combined with astrocytes to assess toxic outcomes in a multi-cellular environment. Along with acute studies, we perform differentiation on assay plates to allow longitudinal studies on an early and a late WOS. Here we used Bis1, a known neurotoxin, to demonstrate cell and WOS specific differences in response, using high content imaging to quantify various parameters of neurite outgrowth, a well established DNT endpoint. Cell viability assays were included to ensure endpoint specificity. We show that Bis1 effects viability of neural progenitors, neurons and astrocytes to different degrees, while also reducing neurite outgrowth in neurons. Further, the toxic effect of Bis1neu on neurons was significantly lowered when neurons were challenged with Bis1 in presence of astrocytes in multi-cellular assays. In longitudinal assays, no differences were observed in neurite outgrowth between the early and late WOS. However, neuron viability was significantly lower in the late WOS. The system described above provides a more complete and robust way to address DNT and combined with suitable compound libraries, will provide valuable inputs for adverse outcome pathway modeling and large scale screening.

Your success is our success!

If you have technical questions regarding the use of your ArunA Biomedical products, we have your Tech Support Team ready. Just send an email to: techsupport@arunabiomedical.com, and a cell culture expert will assist you.

 

ArunA has entered into a technology licensing agreement with the University of Georgia Research Foundation (UGARF) that enables the company to commercialize adherent monolayer neural cell technology developed at the University.  The license allows the company exclusive worldwide rights to develop and commercialize neural cells derived from human pluripotent stem cells including hPSC and human iPSC.

ArunA has also entered into a research and commercialization license with the Wisconsin Alumni Research Foundation (WARF) for nonexclusive rights to their embryonic stem cell patents in research applications.

Product Use Agreement
BIOLOGICAL PRODUCT(S) purchased and DERIVATIVE BIOLOGICAL MATERIALS resulting from the use of ArunA Biomedical BIOLOGICAL PRODUCT(S) shall not be: (i) used for any purpose other than internal research and internal research services, (ii) sold, reengineered and sold or otherwise provided to any third party for any use or purpose, (iii) provided to any agent or other third party for any reason whatsoever, or (iv) used for diagnostic or therapeutic purposes. Acceptance of these terms and conditions shall be deemed by RECIPIENT upon delivery of BIOLOGICAL PRODUCT(S) from ArunA Biomedical. 

Patent US 7,531,354,B2
Patent US 8,178,089
Patent US 6,200,806